Plasma vascular endothelial growth factor levels are a potential therapy-response biomarker for pancreatic cancer.
[INTRODUCTION] Cytokines have long been studied for their role in the pathophysiology of cancer, though their role is varied and complex.
- 표본수 (n) 19
- 연구 설계 randomized controlled trial
APA
Hughes CS, Blyuss O, Kocher HM (2025). Plasma vascular endothelial growth factor levels are a potential therapy-response biomarker for pancreatic cancer.. Frontiers in oncology, 15, 1672385. https://doi.org/10.3389/fonc.2025.1672385
MLA
Hughes CS, et al.. "Plasma vascular endothelial growth factor levels are a potential therapy-response biomarker for pancreatic cancer.." Frontiers in oncology, vol. 15, 2025, pp. 1672385.
PMID
41584580
Abstract
[INTRODUCTION] Cytokines have long been studied for their role in the pathophysiology of cancer, though their role is varied and complex. Cytokines have been mainly developed as a diagnostic or prognostic biomarker using a single measurement from a cohort of patients. Dynamic changes in cytokines may inform us about the prognostic impact of therapy under investigation.
[METHODS] We investigated retrospectively whether a panel of selected cytokines could be used as a potential biomarker to assess treatment response and predict the prognosis of pancreatic ductal adenocarcinoma (PDAC) patients (n=19) treated with combination of Gemcitabine, nab-Paclitaxel and all-trans-retinoic acid (ATRA), in the Phase I trial (STARPAC, NCT03307148). We measured cytokine levels in the plasma samples, from multiple cycle/visit time-points.
[RESULTS] Of the six cytokines (IFN-γ, IL-8, IL-16, VEGF, IL-1RA and RANTES) assessed from the STARPAC trial, we propose that VEGF could serve as a potential biomarker for eventual therapy response, as early as the second chemotherapy cycle (of six).
[DISCUSSION] VEGF as a potential therapy response biomarker will need to be tested in phase II randomized controlled trial.
[METHODS] We investigated retrospectively whether a panel of selected cytokines could be used as a potential biomarker to assess treatment response and predict the prognosis of pancreatic ductal adenocarcinoma (PDAC) patients (n=19) treated with combination of Gemcitabine, nab-Paclitaxel and all-trans-retinoic acid (ATRA), in the Phase I trial (STARPAC, NCT03307148). We measured cytokine levels in the plasma samples, from multiple cycle/visit time-points.
[RESULTS] Of the six cytokines (IFN-γ, IL-8, IL-16, VEGF, IL-1RA and RANTES) assessed from the STARPAC trial, we propose that VEGF could serve as a potential biomarker for eventual therapy response, as early as the second chemotherapy cycle (of six).
[DISCUSSION] VEGF as a potential therapy response biomarker will need to be tested in phase II randomized controlled trial.